Lunai Bioworks (NASDAQ:LNAI) Cut to “Sell” at Wall Street Zen

Lunai Bioworks (NASDAQ:LNAI) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lunai Bioworks in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Lunai Bioworks has an average rating of “Sell”.

Lunai Bioworks Stock Performance

LNAI stock opened at $0.55 on Friday. The company has a market capitalization of $13.19 million, a P/E ratio of -7.79 and a beta of 0.46. Lunai Bioworks has a twelve month low of $0.52 and a twelve month high of $14.00. The company has a 50 day moving average of $0.87.

Lunai Bioworks (NASDAQ:LNAI) last issued its earnings results on Tuesday, February 17th. The company reported ($0.08) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC purchased a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent filing with the Securities & Exchange Commission. 71.41% of the stock is currently owned by hedge funds and other institutional investors.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.